News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
Tele-MANAS has counseled more than 3,50,000 people till date and currently provides counseling to 2000 people through 44 Tele Manas Cells
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Also to be launched Scheme for promotion of Research and Innovation in Pharma MedTech Sector (PRIP)
30 beneficiaries avail of services per minute
The medical center at the Buddh International Circuit will be under the care of the Indraprastha Apollo Hospital team
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Free Treatment, investigations and sex change surgery along with other facilities will be available at these OPDs for the Transgender community
Subscribe To Our Newsletter & Stay Updated
